Biotron Ltd logo

Biotron Ltd

NEW
ASX:BIT (Australia)  
A$ 0.0030 +0.0010 (+50%) Jun 30
At Loss
P/B:
3.00
Market Cap:
A$ 5.40M ($ 3.81M)
Enterprise V:
A$ 5.02M ($ 3.54M)
Volume:
1.22M
Avg Vol (2M):
890.61K
Trade In:
Volume:
1.22M
At Loss
Avg Vol (2M):
890.61K

Business Description

Description
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.7
Interest Coverage
No Debt
Piotroski F-Score
4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year FCF Growth Rate
30.7

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
64.14
9-Day RSI
60.56
14-Day RSI
57.59
3-1 Month Momentum %
-20
6-1 Month Momentum %
-33.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.47
Quick Ratio
1.47
Cash Ratio
1.42

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-17
Shareholder Yield %
-33.84

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-156.55
ROA %
-100.1
ROIC %
-159.84
3-Year ROIIC %
438.96
ROC (Joel Greenblatt) %
-34341.18
ROCE %
-157.4
Moat Score
2
Tariff Resilience Score
6

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
3
EV-to-EBIT
-2.58
EV-to-EBITDA
-2.59
EV-to-FCF
-4.01
Earnings Yield (Greenblatt) %
-38.75
FCF Yield %
-35.58

Financials

ASX:BIT's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Biotron Ltd Executives

Details

GF Value™

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.002
Beta -0.6085
3-Year Sharpe Ratio -0.28
3-Year Sortino Ratio -0.49
Volatility % 87.2
14-Day RSI 57.59
14-Day ATR (A$) 0.000448
20-Day SMA (A$) 0.002225
12-1 Month Momentum % -
52-Week Range (A$) 0.002 - 0.005
Shares Outstanding (Mil) 2,701.87

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biotron Ltd Filings

Filing Date Document Date Form
No Filing Data

Biotron Ltd Stock Events

Financials Calendars
Event Date Price (A$)
1.04134:1 Stock Split 2006-03-27 0.19 (+0.00%)
Show
Entries

Biotron Ltd Frequently Asked Questions

What is Biotron Ltd(ASX:BIT)'s stock price today?
The current price of ASX:BIT is A$0.00. The 52 week high of ASX:BIT is A$0.01 and 52 week low is A$0.00.
When is next earnings date of Biotron Ltd(ASX:BIT)?
The next earnings date of Biotron Ltd(ASX:BIT) is .
Does Biotron Ltd(ASX:BIT) pay dividends? If so, how much?
Biotron Ltd(ASX:BIT) does not pay dividend.

Press Release

Subject Date
Biotron Drug Effective Against COVID-19 In Animals 2021-11-25
10/Page

Articles on Biotron Ltd

No articles.